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A simple, rapid, and sensitive method based on liquid chromatography-tandem mass spectrometry for 
the quantitative determination of simvastatin in human plasma was developed and validated. After a 
simple extraction with methyl tert-butyl ether, the analyte and internal standard (lovastatin) were analyzed 
using reverse-phase liquid chromatography, on a Kinetex C18 column (100 × 4.6 mm, 2.6 μm) using 
acetonitrile: ammonium acetate (2 mM + 0.025 % formic acid) (70: 30, v/v) as a mobile phase in a run 
time of 3.5 min. Detection was carried out using electrospray positive ionization mass spectrometry in 
the multiple-reaction monitoring mode. The method was linear over 0.04-40.0 ng/mL concentration 
range. The mean extraction recovery of simvastatin was 82% (RSD within 15%). Intraday and interday 
precisions (as relative standard deviation) were all ≤8,7% with accuracy (as relative error) of ±8%. This 
rapid and reliable method was successfully applied for a bioequivalence study of 40 mg of simvastatin 
orally disintegrating tablets in 44 healthy volunteers, showing that this method is suitable for the 
quantification of simvastatin in human plasma samples for pharmacokinetics and bioequivalence studies.
Uniterms: Simvastatin/determination. Liquid chromatography/quantitative analysis. Tandem mass 
spectrometry/quantitative analysis. Human plasma/determination of simvastatin. Simvastatin/
bioequivalence. Simvastatin/pharmacokinetics.
Desenvolveu-e e validou-se um método simples, rápido e sensível baseado na cromatografia líquida 
acoplada à espectrometria de massas em tandem para a quantificação de sinvastatina em plasma humano. 
Após um simples preparo de amostras utilizando extração com éter metil-terc-butílico, o analito e seu 
padrão interno (lovastatina) foram analisados por cromatografia líquida de fase reversa, em uma coluna 
Kinetex C18 (100 mm x 4,6 mm x 2,6 μm), utilizando uma fase móvel composta de acetonitrila:acetato 
de amônio (2 mM + 0,025% ácido fórmico) (70:30, v/v) em tempo total de corrida de 3,5 min. A 
detecção foi realizada por espectrometria de massas utilizando a ionização por electrospray no modo 
positivo e monitorando os íons pelo sistema de monitoramento de reação múltipla. O método apresentou 
linearidade na faixa de 0,4 – 40,0 ng/mL. A recuperação média obtida para sinvastatina foi de 82% (DPR 
menor que 15%). A precisão intradia e interdias (como desvio padrão relativo) foi ≤8,7% com exatidão 
(como erro relativo) de ± 8%. Este método rápido e confiável foi aplicado com sucesso em um estudo 
de bioequivalência de comprimidos de desintegração oral de sinvastatina 40 mg em voluntários sadios, 
mostrando que este método é adequado para a quantificação de sinvastatina em plasma humano para 
estudos farmacocinéticos e bioequivalência.
Unitermos: Sinvastatina/determinação. Cromatografia líquida/análise quantitativa. Espectrometria de 
massas em tandem/análise quantitativa. Plasma humano/determinação de sinvastatina. Sinvastatina/
bioequivalência. Sinvastatina/farmacocinética.
S. C. R. Silva, G. R. Rezende, V. B. Boralli544
INTRODUCTION
Simvastatin is a cholesterol-lowering agent (Hoffman 
et al., 1986) and acts as a 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase inhibitor effective 
in the treatment of hypercholesterolemia. It is an inactive 
hydrophobic lactone prodrug, which is metabolized in 
vivo to several more polar, pharmacologically active, 
compounds, most notably the corresponding hydroxy acid 
form, simvastatin acid (Mauro, 1993).
After an oral dose, the concentration of simvastatin 
in plasma is very low, probably because of high first-pass 
hepatic extraction resulting in low oral bioavailability 
(5%) (Mauro, 1993; Vickers et al., 1990). Therefore, 
sensitive and selective methods for the determination of 
simvastatin in plasma have been required for therapeutic 
drug level monitoring.
Several methods for simvastatin determination in 
plasma have been reported, including gas chromatography-
mass spectrometry (GC-MS) (Takano, Abe, Hata, 1990), 
liquid chromatography coupled to UV detector (LC-UV) 
(Carlucci et al., 1992), and liquid chromatography coupled 
to fluorescence detector (LC-fluorescence) (Ochiai et al., 
1997). However, GC-MS and LC-fluorescence methods 
include analyte derivatization with a generally complicated 
sample preparation procedure; LC-UV methods are not 
sensitive enough for measuring drug levels in plasma at 
therapeutic dose.
UPLC-MS/MS (u l t ra -per formance  l iquid 
chromatography tandem mass-spectrometry) has 
numerous advantages, for example, very selective 
separations, comparatively short analysis times, and 
simple preliminary treatment of the sample.
The present paper reported an original UPLC-MS/
MS method for the quantification of simvastatin in human 
plasma, requiring a simple sample treatment using one-
step extraction with a run time of only 3.5 min for each 
sample. This method exhibited excellent performance in 
terms of recovery, precision, accuracy, matrix effect, and 
low detectability (LLOQ of 0.4 ng/mL). The suitability 
of this UPLC-MS/MS method for routine bioanalysis 
was proven by its application in sample quantification of 




Simvastatin USP reference standard (lot no. I1H070) 
and the internal standard (lovastatin, lot no. H4K027) were 
purchased from United States Pharmacopeia (Rockville, 
USA); the reference formulation was simvastatin tablet 
(each tablet containing 40 mg of simvastatin) provided 
by Merck Sharp & Dohme Ltd. (Northumberland, UK), 
and the test formulation was simvastatin tablet (40 mg) 
provided by a Brazilian company (protected name 
by contractual confidentiality). Ammonium acetate, 
acetonitrile, and methyl tert-butyl ether (MTBE) were 
HPLC grade purchased from J.T. Baker (Phillipsburg, 
NJ, USA). Formic acid was from Sigma-AldrichTM (St. 
Louis, Missouri, USA), and ammonium hydroxide was 
from VetecTM (Rio de Janeiro, RJ, Brazil). Deionized water 
was prepared through the Milli-Q Plus Ultra-Pure water 
system (Millipore Corporation, Bedford, MA, USA). 
Heparinized blank (drug-free) human plasma was obtained 
from CEBIO clinic step, Belo Horizonte hospital (Belo 
Horizonte, MG, Brazil).
Instrumentation
The UPLC-MS/MS system consisted of a Waters 
Acquity UPLCTM H-Class system coupled to a triple 
quadrupole TQDTM mass spectrometer (Waters, Milford, 
MA, USA), which is equipped with electrospray ionization 
(ESI) source for ion production. Data acquisition and 
integration were controlled by MassLynxTM software 
(Version 4.1, Waters).
LC-MS/MS conditions
The chromatographic separation was performed 
on a Kinetex C18 column (100 × 4.6 mm I.D., 2.6 μm, 
Phenomenex, Torrance, CA, USA) maintained at 45 °C. 
The mobile phase consists of a mixture of acetonitrile: 
ammonium acetate (2 mM + 0.025% formic acid) (70:30, 
v/v) at a flow rate of 1.0 mL/min. The column effluent was 
split so that approximately 0.2 mL/min entered the mass 
spectrometer, and the injection volume via autosampler 
(set as 5 °C) was 20 μL. The ESI source was operated 
on the positive ionization mode using multiple-reaction 
monitoring (MRM) of transitions of the protonated 
molecular ions. These transitions (m/z) with associated 
cone voltage (V) and collision energies (eV) were as 
follows: simvastatin 419.3>199.0, 22, 10, and lovastatin 
405.0>199.0, 18, 14. For simvastatin and lovastatin (IS), 
the source parameters maintained were desolvation gas 
flow (nitrogen): 550 L/h, cone gas flow (nitrogen): 50 L/h, 
capillarity voltage: 3.8 kV, source temperature: 140 °C, 
desolvation temperature: 450 °C, extractor 3.0 V. Dwell 
time set was 0.15 s for both analytes.
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Preparation of standard and quality control (QC) 
samples
A stock solution (1 mg/mL) of simvastatin was 
diluted with acetonitrile: water (50: 50, v/v) to produce 
standard solutions with concentrations of 4, 10, 25, 50, 
100, 150, 250, and 400 ng/mL. Quality control (QC) 
solutions were prepared independently at low, medium, 
and high concentrations (12, 120, and 300 ng/mL) in the 
same way. A 50-μL aliquot of each standard solution was 
mixed with 450 μL of pooled blank plasma (obtained 
from healthy human volunteers) to produce calibration 
standards of simvastatin with concentrations of 0.4, 1, 
2.5, 5, 10, 15, 25, and 40 ng/mL. QC samples (1.2, 12, 
and 30 ng/mL) were generated from QC solutions with the 
same procedure. A stock solution (1 mg/mL) of lovastatin 
(IS) was prepared with acetonitrile: water (50: 50, v/v) 
and diluted in acetonitrile to give a final concentration of 
0.15 μg/mL. The solutions were stored at 5 °C, and the 
plasma samples were stored in a -20 °C freezer.
Sample preparation
Plasma samples (500 μL) were placed into 2.0 mL 
Eppendorf tubes. After adding 50 μL of IS, the sample 
extraction was followed by adding 50 μL of 50 mM 
ammonium acetate buffer (pH 4.5) and extracted with 
1000 µL of methyl tert-butyl ether (MTBE) for 5 min. 
After centrifugation at 5000 g/5 °C for 5 min, 850 µL 
of the organic phase was transferred to another tube and 
evaporated to dryness under a gentle stream of air at room 
temperature. The residues obtained were reconstituted in 
200-µL aliquots of mobile phase and 20 µL injected into 
the UPLC-MS/MS system.
Method validation
Method validation was performed according to 
ANVISA Guide for analytical and bioanalytical method 
validation (ANVISA, 2003) and according to FDA 
Guidance for Industry, Bioanalytical Method Validation 
(US Food and Drug Administration, 2001). Selectivity was 
assessed by comparing chromatograms of spiked plasma 
samples in the lower limit of quantification (LLOQ) 
concentration with plasmas from six different individuals. 
Linearity, in the range of 0.4-40 ng/mL, was evaluated 
using the assay of three independent analytical curves on 
3 different days by weighted linear regression (1/x2) of 
analyte/IS peak area ratios. Lower limit of quantification 
(LLOQ) was defined as the lowest concentration of analyte 
that could be quantitatively determined with precision of 
≤ 20% and accuracy of 80-120% (ANVISA, 2003; Food 
and Drug Administration, 2001). Accuracy (as relative 
error - RE) and precision (as relative standard deviation - 
RSD) were determined by assay of seven replicates of low, 
medium, and high QC samples on 3 different days. The 
intraday and interday precisions were required to be lower 
than 15% and the accuracy to be within ± 15%, except 
at LLOQ, where it should not exceed 20% (ANVISA, 
2003; Food and Drug Administration, 2001). Recovery 
was determined by comparing the mean peak areas for 
five replicate analysis of low, medium, and high QC 
samples with those of blank plasma extracts reconstituted 
with the corresponding QC solutions. Recovery of the 
analyte need not be 100%, but the extent of recovery of 
an analyte and the internal standard should be consistent, 
precise, and reproducible (ANVISA, 2003; Food and Drug 
Administration, 2001). Matrix effects can be described as 
the difference between the mass spectrometric response 
for an analyte in standard solution and the response for 
the same analyte in a biological matrix, such as plasma 
(Kebarle, Tang, 1993). Matrix effects were carried out by 
monitoring the instrument response of a constantly infused 
analytes after injecting an extract from an extracted blank 
sample into the UPLC-MS/MS system. This approach 
identifies chromatographic regions where an analyte 
would be most susceptible to suppression or enhancement. 
The stability of analytes was evaluated under all the 
storage conditions at two QC concentrations (low and 
high). The tested samples were compared with freshly 
prepared samples in five replicates. The long-term stability 
was assessed after storage of QC samples at –20 °C for 
90 days. For the short-term stability, QC samples were 
kept at room temperature for 19 h. The freeze/thaw 
stability test was performed after three complete freeze/
thaw cycles (- 20 °C to room temperature). Stability of 
processed samples was assessed by injection of extracted 
QC samples after conservation for 73 h at 5 °C. The stock 
solutions of simvastatin and lovastatin stored at 5 °C were 
compared with freshly prepared solutions after 60 days, 
and the same procedure was done to the solutions stored 
at room temperature for 18 h.
Pharmacokinetic study
A randomized, single-dose, two-period, two-
sequence, and crossover design was used for the 
bioequivalence assessment of two branded simvastatin 
tablets, approved by the Research Ethic Committee 
of Belo Horizonte hospital, accredited by CONEP - 
National Commission on Ethics Research (from Brazil). 
The bioequivalence study was followed by a washout 
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period of one week. In each study period, volunteers 
were required to fast for approximately 8 h before the 
dosing. The formulations were administered with 200 mL 
water. Water and food were not allowed until 4 h after 
administration. Standardized meals were provided after 4, 
7, and 11 h of blood sampling. A total of forty-four male 
and female volunteers (age 18 – 40 years; body mass index 
18.5-27.0 kg/m2) were considered to be in good health 
based on their medical history, physical examination, and 
routine laboratory tests. All volunteers read the protocol 
and gave written informed consent before entering the 
study. They were instructed to abstain from using any 
medications for at least one week before and during the 
study and from smoking and taking alcohol, caffeine, and 
xanthenes at least 48 h before administering the study 
drugs and throughout the study. Blood samples were 
collected into heparinized tubes before administration and 
at 0.33, 0.66, 1, 1.33, 1.66, 2, 2.33, 2.66, 3, 3.33, 3.66, 4, 
6, 8, 10, 12, and 24 h post-dose (40 mg simvastatin tablet). 
Plasma was separated immediately by centrifugation at 
1800 g for 15 min and stored at –20 °C before analysis. 
The analytical batch consisted of blank, blank with internal 
standard (zero), eight calibration standards, and volunteer 
plasma samples involved in the study with QC samples 
interspersed (low, medium, and high concentrations).
RESULTS AND DISCUSSION
LC-MS/MS conditions
The ion mass spectra of each analyte are shown 
in Figure 1. The spectra were similar to those shown 
in previous reports for simvastatin and lovastatin 
(Apostolou et al., 2008; Nováková et al., 2009). The 
most abundant product ion of each analyte was selected 
for MRM monitoring. In both analytes, protonated 
molecule [M+H]+ was monitored in electrospray positive 
ionization mode. Therefore, the ion transitions m/z 
419.3>199.0 and 405.0>199.0 were selected for MRM 
of the simvastatin and the IS, respectively. Argon was 
used as collision gas, and collision energy was optimized 
for each analyte.
UPLC was used as separation method for the analysis 
of simvastatin and lovastatin. The chromatographic 
conditions were investigated on several different reversed 
phase columns (BEH C18, Symmetry C18, Kinetex C18) 
to obtain a suitable retention time and symmetrical peak 
shape. To get the shortest analysis time and avoid the 
matrix effects, different percentages of acetonitrile were 
tested. In early experiments, acetonitrile: ammonium 
acetate (2 mM + 25% formic acid) (85: 15, v/v) was 
applied as mobile phase, but when it was changed for 
acetonitrile: ammonium acetate (2 mM + 0,025% formic 
acid) (70: 30, v/v), the signal achieved the maximum 
response and had better peak shapes. On the other hand, 
these changes greatly increased the running time. This 
mobile phase was deemed unacceptable for practical 
routine use. Therefore, to reduce the running time, the 
mobile phase flow was increased to 1.0 mL/min with a split 
ratio of 1: 4 (MS/MS:waste). This last condition allowed 
a running time of 3.5 min with enough simvastatin area 
response at LLOQ concentration.
The best combinations of peak shape and retention 
time were achieved using Kinetex C18 column (100 mm 
x 4.6 mm, 2.6 μm) using acetonitrile: ammonium acetate 
(2 mM + 0,025% formic acid) (70: 30, v/v) as a mobile 
phase, which was operated isocratically in 1.0 mL/min at 
a column temperature of 45 °C.
Sample preparation
Different methods of sample preparation including 
solid-phase extraction (SPE), protein precipitation, and 
liquid-liquid extraction (LLE) with various organic 
solvents (such as ethyl acetate, hexane, dichloromethane, 
FIGURE 1 - Ion mass spectra [M+H]+: (A) simvastatin precursor 
ion, (B) simvastatin product ion, (C) lovastatin precursor ion, 
and (D) lovastatin product ion.
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chloroform, and methyl tert-butyl ether) were evaluated. 
SPE required lengthy extraction procedure when compared 
with a simple LLE. Protein precipitation introduces serious 
matrix effects. Besides, a dirty extract may damage 
the equipment during bioanalytical routine. LLE using 
MTBE had numerous advantages, for example, very 
simple sample preparation, clean extracts, high extraction 
efficiency, and fast organic solvent evaporation. The 
addition of ammonium acetate buffer (pH 4.5) to plasma 
before extraction enhanced the recovery of simvastatin 
and IS. It could also help in displacing drug from protein 
and to prevent interconversion between simvastatin and 
simvastatin acid, at the same time maintaining the acidic 
analytes in a nonionic lipophilic form. Consistent and 
reproducible recoveries were obtained using MTBE as 




There was no significant interference from 
endogenous substances in human plasma at the analytes 
retention time window. Figure 2 shows typical MRM 
chromatograms of blank human plasma and a plasma 
sample spiked at the LLOQ (0.4 ng/mL) concentration 
in both ion transitions determined (m/z 419.3>199.0 and 
405.0>199.0). The chromatograms show excellent peak 
shape for both the analyte and IS, and the retention times 
were short enough to allow a run time of 3.5 min, which 
is suitable for routine analysis. The areas observed at the 
retention time windows of simvastatin and lovastatin were 
less than 20% of their LLOQ area (m/z 419.3>199.0), 
and it was less than 5% IS area, as observed in the LLOQ 
sample (m/z 405.0>199.0).
FIGURE 2 - Blank human plasma chromatograms m/z 419.3>199.0 (A); 405.0>199.0 (B) and a plasma sample spiked at the LLOQ 
(0.4 ng/mL) concentration m/z 419.3>199.0 (C); 405.0>199.0 (D).
Linearity and sensitivity
The eight-point calibration curve obtained using 
weighted linear regression (1/x2) showed good linearity 
over the whole concentration range (0.4–40 ng/mL), which 
covered the concentrations found in human plasma after 
administration of simvastatin in this pharmacokinetic 
study. The correlation coefficient was better than 0.99, and 
a typical equation of calibration curve was y = 0.121288x 
- 0.0000502624. The least-squares linear regression 
was used to mathematically define the calibration line. 
A weighting factor (1/x2) was used to avoid bias at the 
calibration line in favor of the high standards. This was 
especially important because a wide calibration range was 
selected. The LLOQ (defined as the lowest concentration 
that could be analyzed with acceptable accuracy and 
precision (20%) was 0.4 ng/mL with a mean accuracy of 
103.3% and a mean precision of 12.3% (n = 7).
Accuracy and precision
The assay procedure proved to be precise and 
accurate. The intraday (n = 7) and the interday precision 
(n = 3 days, seven replicates per day) showed results 
lower than 15% RSD, for the three QC concentrations. 
The intraday and the interday accuracy, expressed as 
a percentage of nominal values, showed values within 
±15%, for all three QC concentrations (Table I).
Recovery and matrix effects
The most important parameter affecting the 
simvastatin recovery is the pH value used in the extraction. 
The extraction conditions were evaluated to achieve 
maximum extraction efficiency for both analytes and, 
at the same time, minimum interconversion between 
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lactone and acid form. The optimum pH for the extraction 
buffer was between 4 and 5. Any pH>5 would produce 
lower extraction efficiency. A pH of 4.5 was chosen after 
evaluation of three pH values between 4 and 5.
The samples were purified using a simple process of 
liquid - liquid extraction (LLE) using MTBE as extractor 
solvent, which allowed good recovery for simvastatin and 
lovastatin compared with other tested solvents. As shown 
in Table II, the mean extraction recoveries measured from 
the LLE extraction procedure were approximately 80% 
for both drugs.
The postcolumn infusion method was enough 
in matrix effects determination. As shown in Figure 3, 
there was no ion suppression or ion enhancement at the 
chromatographic retention times of both analytes. This 
technique allows one to intelligently modify the elution 
time of an analyte so that it does not fall into suppression/
enhancement zones.
The evaluation of possible matrix effects is an 
essential part of method development/validation for any 
LC-MS-MS method. If relevant matrix effects are found, 
they should be reduced or eliminated by the optimization of 
chromatographic conditions, improving the sample clean-
up and/or by changing the type of ionization employed. 
Typically, suppression or enhancement of analyte response 
is accompanied by diminished precision and accuracy of 
subsequent measurements. Thus, matrix effects can limit 
the utility of LC-MS/MS for quantitative analysis.
Stability
Stability results in Table III demonstrate that 
simvastatin is stable with deviation <15% under the 
indicated conditions for the pharmacokinetic study.
The stock solutions of simvastatin and lovastatin 
stored at 5 °C per 60 days and at room temperature/18 h 
were compared with fresh solutions and were considered 
stable at those conditions.
The stability of the analytes in human plasma, at 
storage conditions, were evaluated over a period equal to 
the typical sample preparations, sample handlings, and 
analytical run times.
Pharmacokinetic study
The validated UPLC-MS/MS method was success-
FIGURE 3 - Instrument response from constantly infused 
analytes after injecting an extracted blank sample into the 
UPLC-MS/MS system (A); UPLC-MS/MS injection of both 
analytes in mobile phase solution, not concomitant, just for 
comparison (B).
TABLE I - Precision and accuracy for simvastatin in human plasma
Spiked concentration (ng/mL) 1.2 ng/mL 12.0 ng/mL 30.0 ng/mL
Mean concentration intraday (ng/mL) 1.2 1.3 1.1 13.0 12.5 11.6 31.3 30.1 28.0
Precision intraday (RSD%) 6.1 6.3 4.5 4.7 6.2 8.7 7.3 5.3 6.0
Mean accuracy intraday (%) 103.5 104.9 94.2 108.1 104.0 97.0 104.4 100.3 93.3
Mean concentration interday (ng/mL) 1.2 12.3 29.6
Precision interday (RSD%) 7.3 7.9 7.5
Mean accuracy interday (%) 100.6 102.7 98.7
RSD: relative standard deviation; Intraday assays: n = 7; Interday assays: n = 3
TABLE II - Extraction recovery of simvastatin and lovastatin







RSD (%) 12.7 12.4 1.4 10.6
Recovery (%) 93.0 79.1 76.4 82.1
RSD: relative standard deviation (n = 5)
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TABLE III - Stability of simvastatin in human plasma under various conditions (n = 5)















human plasma at room 





























RE: relative error (n = 5)
TABLE IV - Pharmacokinetic parameters for test and reference drugs in healthy subjects in bioequivalence study





Cmax (ng/mL) 9.0 ± 5.1 5.8 ± 3.7 55,9 – 72,7 
AUC0-t (h.ng/mL) 35.5 ± 18.7 36.1 ± 19.5 88,8 – 112,6 
AUC0-∞ (h.ng/mL) 50.4 ± 41.3 68.8 ± 79.3 106,4 – 150,2
tmax (h) 1.4 ± 1.2 2.3 ± 2.7 -
t1/2 (h) 10.5 ± 12.6 18.0 ± 21.4 -
Kel 0.1 ± 0.1 0.1 ± 0.1 -
Cmax: peak concentration; AUC0-t: area under the plasma concentration time curve from zero to the last nonzero concentration time; 























































FIGURE 4 - Mean plasma concentration-time profile of healthy 
volunteers, after single oral dose administration of reference and 
test products of simvastatin tablets.
fully applied to a bioequivalence study in healthy human 
volunteers who received 40-mg tablet of simvastatin 
reference and test formulations under fasting conditions.
The samples were processed based on the proposed 
quick and simple extraction procedure for the quantification 
of simvastatin in human plasma. The method was 
sensitive enough to monitor the simvastatin plasma level 
concentration up to 24 h after oral dose.
The basic pharmacokinetics parameters (Cmax, 
AUC0-t, AUC0-∞, tmax, and t1/2) obtained for test and 
reference drugs in healthy subjects in this bioequivalence 
study were summarized in Table IV. The mean plasma 
concentration-time profile of healthy human volunteers, 
after single oral dose administration of reference and test 
products of 40 mg simvastatin tablets is shown in Figure 4.
After natural logarithmic transformation using 
general linear model procedure to evaluate the effects of 
sequence, period, and formulation, at significance level 
(α) of 0.05, no statistically significant effect of sequence 
was found, showing that the washout period was enough 
to not cause carryover effects. However, the period effect 
and formulation effect were statistically significant with 
results of 0.0091 for Cmax (period effect); <0.0001 for Cmax, 
and 0.0276 for AUC0-∞ (formulation effect). These results 
can suggest that there was some variability between test 
and reference formulations.
These findings do not confirm the bioequivalence 
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between 40 mg test sample and the reference product in 
terms of rate and extent of absorption.
CONCLUSIONS
A quick, simple, selective, precise, and accurate 
UPLC-MS/MS method was developed and validated for 
the quantification of simvastatin in human plasma. The 
main advantages of this method were as follows: simple 
and fast sample preparation (one-step extraction), excellent 
recovery, minor matrix effects, low chromatographic run 
time (only 3.5 min for each sample), and low detectability 
(LLOQ of 0.4 ng/mL). The method was shown to be 
adequate and reliable for application to pharmacokinetics 
and bioequivalence studies of simvastatin.
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